These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 24750350

  • 1. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
    Verlinden A, Jansens H, Goossens H, van de Velde AL, Schroyens WA, Berneman ZN, Gadisseur AP.
    Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350
    [Abstract] [Full Text] [Related]

  • 2. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
    Ugarte-Torres A, Villasis-Keever A, Hernández-Bribiesca ME, Crespo-Solis E, Ruiz-Palacios GM, Sifuentes-Osornio J, Ponce-De-León-Garduño A.
    Rev Invest Clin; 2006 Oct; 58(6):547-54. PubMed ID: 17432285
    [Abstract] [Full Text] [Related]

  • 3. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
    Reuter S, Kern WV, Sigge A, Döhner H, Marre R, Kern P, von Baum H.
    Clin Infect Dis; 2005 Apr 15; 40(8):1087-93. PubMed ID: 15791505
    [Abstract] [Full Text] [Related]

  • 4. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
    Chong Y, Yakushiji H, Ito Y, Kamimura T.
    Int J Infect Dis; 2011 Apr 15; 15(4):e277-81. PubMed ID: 21324723
    [Abstract] [Full Text] [Related]

  • 5. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
    Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R.
    Eur J Clin Microbiol Infect Dis; 2005 Feb 15; 24(2):111-8. PubMed ID: 15714332
    [Abstract] [Full Text] [Related]

  • 6. [Gram-negative bacteremia in neutropenic patients with hematologic disorders. Experiences with prophylactic use of fluoroquinolones].
    Sinkó J, Cser V, Konkoly Thege M, Masszi T.
    Orv Hetil; 2011 Jul 03; 152(27):1063-7. PubMed ID: 21676672
    [Abstract] [Full Text] [Related]

  • 7. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
    Martino R, Subira M, Altés A, López R, Sureda A, Domingo-Albós A, Pericas R, Brunet S.
    Acta Haematol; 1998 Jul 03; 99(4):206-11. PubMed ID: 9644298
    [Abstract] [Full Text] [Related]

  • 8. Extended-spectrum beta-lactamase gram-negative sepsis following prostate biopsy: implications for use of fluoroquinolone prophylaxis.
    Cannon GM, Smaldone MC, Paterson DL.
    Can J Urol; 2007 Aug 03; 14(4):3653-5. PubMed ID: 17784990
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.
    Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, Martí JM, Estany C.
    Cancer; 2003 Jan 15; 97(2):419-24. PubMed ID: 12518366
    [Abstract] [Full Text] [Related]

  • 14. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
    Poon LM, Jin J, Chee YL, Ding Y, Lee YM, Chng WJ, Chai LY, Tan LK, Hsu LY.
    Singapore Med J; 2012 Nov 15; 53(11):720-5. PubMed ID: 23192498
    [Abstract] [Full Text] [Related]

  • 15. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines.
    Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C, European Conference on Infections in Leukemia (ECIL).
    J Infect; 2018 Jan 15; 76(1):20-37. PubMed ID: 29079323
    [Abstract] [Full Text] [Related]

  • 16. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014.
    Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M, Weisser M, Götting T, Widmer AF, Theilacker C, Hospital Infection Surveillance System for Patients with Haematologic/Oncologic Malignancies Study Group (ONKO-KISS).
    J Infect; 2018 Jul 15; 77(1):68-74. PubMed ID: 29883599
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Fluoroquinolones to prevent bacterial infection in children with chemotherapy induced neutropenia: is it reasonable?].
    Dubos F, Delebarre M, Lagrée M.
    Arch Pediatr; 2013 Nov 15; 20 Suppl 3():S90-3. PubMed ID: 24360309
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.